Publication
Title
Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab
Author
Institution/Organisation
Belgian IBD Research and Development group (BIRD)
Abstract
Background and Aims: Vedolizumab is an IgG1 anti-alpha 4 beta 7 integrin antibody approved for the treatment of inflammatory bowel diseases[IBD], but without clear safety data during conception, pregnancy and nursing. Animal studies showed that mucosal vascular addressin cell adhesion molecule 1[MAdCAM-1] is expressed by maternal vessels in the placenta and recruits alpha 4 beta 7-expressing cells that are considered important for maternal/fetal tolerance. Blocking this interaction by vedolizumab might affect this process. We aimed to evaluate pregnancy outcomes in vedolizumab-treated female IBD patients. Methods: We conducted a retrospective, multicentre Belgian observational study. Details on disease activity, prenatal complications, delivery and neonatal outcome were collected through a case report form. Results: Twenty-four pregnancies were reported. Five women had active disease at conception and one patient flared during pregnancy. There were 23 live births. Complications were observed in 25% of pregnancies[premature rupture of membranes, pre-eclampsia, miscarriage, elective termination and stillbirth] and in 35% of infants[prematurity, intra-uterine growth retardation, small for gestational age and congenital malformations including hip dysplasia, pulmonary valve stenosis and Hirschprung's disease]. Vedolizumab was continued throughout pregnancy in two females and stopped in the 1st and 2nd trimester in five and 16 patients, respectively. For live born children, the median [interquartile range] gestational age, weight and Apgar score 5 min after birth were 39 [37-39.6] weeks, 3270 [3080-3585] grams and 10 [9-10], respectively. Conclusions: Although several complications were observed, both in mothers and in newborns, no firm conclusions can be drawn. Awaiting prospective and controlled registries, vigilance and strict follow-up of pregnant patients treated with vedolizumab seems mandatory.
Language
English
Source (journal)
Journal of Crohn's and colitis. - Place of publication unknown
Source (book)
Belgian Week of Gastroenterology, FEB 22, 2018, Antwerp, BELGIUM
Publication
Oxford : Oxford univ press , 2019
ISSN
1873-9946
DOI
10.1093/ECCO-JCC/JJY142
Volume/pages
13 :1 (2019) , p. 12-18
ISI
000459355900003
Pubmed ID
30281093
Full text (Publisher's DOI)
Full text (publisher's version - intranet only)
UAntwerpen
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 28.09.2021
Last edited 09.10.2023
To cite this reference